Browsing Tag
Johnson & Johnson
106 posts
Legend Biotech soars 42% on ASCO data as CAR-T momentum extends from blood cancers toward solid tumors
Legend Biotech soared 42% on ASCO data: a survival readout for myeloma CAR-T CARVYKTI plus early solid-tumor results for LB2102. Big ramp, but still loss-making.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies
Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence?
Johnson & Johnson shows new TECNIS PureSee data at ASCRS 2026 as JNJ eyes deeper ophthalmology upside
Johnson & Johnson unveiled new TECNIS PureSee data at ASCRS 2026. Read how it could reshape cataract surgery growth and JNJ’s medtech outlook.
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.
Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit
Johnson & Johnson faces a new talc verdict in Philadelphia. Find out why even a small award still matters for investors and long-term strategy.
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
Johnson & Johnson’s AKEEGA clears major EU hurdle with CHMP nod for mHSPC BRCA mutation indication
Johnson & Johnson’s EU backing for AKEEGA’s expanded prostate cancer label could reshape its oncology strategy and precision medicine footprint in 2026.
J&J’s CAPLYTA nearly doubles remission rates in Phase 3 MDD trial
Find out how Johnson & Johnson’s CAPLYTA is redefining remission in depression with six-month data that could reshape MDD treatment benchmarks.